Find out more about the NICE Diagnostics Advisory Committee members by reading their biographies.
Dr Mark Kroese MB, ChB, DPH, FFPH, FRCP(Ed), MRCGP
Consultant in Public Health Medicine, PHG Foundation
Mark Kroese is a Consultant in Public Health Medicine at the PHG Foundation, Cambridge and was appointed Public Health Advisor to the UK Genetic Testing Network in 2006. Prior to joining the PHG Foundation, Mark worked for nearly 7 years as Consultant in Public Health Medicine at Peterborough Primary Care Trust.
His specialist interests are in the evaluation and regulation of genetic tests and the commissioning of clinical genetics services.
Ms Elizabeth Adair
Biography to follow.
Mr John Bagshaw
In-Vitro Diagnostics Consultant
Biography to follow.
Professor Enitan Carrol
Chair in Paediatric Infection, University of Liverpool
Biography to follow.
Dr Owen Driskell
Biography to follow.
Dr Simon Fleming MSc, MD, FRCPath
Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Cornwall Hospital
Simon Fleming is a Consultant in Clinical Biochemistry and Metabolic Medicine in Cornwall and Honorary Teacher at the Peninsula College of Medicine and Dentistry. He trained in London and Newcastle upon Tyne and has specialist interests in lipidology, diabetes, clinical nutrition and cardiovascular research.
He has previously worked as a reviewer for National Confidential Enquiry into Patient Outcome and Death (NCEPOD) and the HTA Diagnostics Programme.
Dr James William Gray
Consultant Microbiologist, Department of Microbiology, Birmingham Children’s Hospital
Jim Gray has been a Consultant Microbiologist at Birmingham Children’s and Women’s Hospitals since 1995. Clinical and research interests include diagnostic test accuracy studies and improving the laboratory-clinical interface, in particular to ensure that key laboratory results are reported and appropriately acted upon without delay.
Recent service innovations include the introduction of Advance Laboratory Practitioners, multidisciplinary laboratory working to support infection control and antibiotic decision making on an out of hours basis. Research interests include point of care testing for group B streptococcus screening in labouring women and improved blood culture technology to support antibiotic stewardship in neonates.
Jim has worked on several NICE Programmes, including being a member of two Guideline Development Groups and a Standing Member of a Rapid Clinical Guideline Updates Committee. He is an Expert Advisor for the British National Formulary for Children (BNF-C), and has served on a number of national committees relating to paediatric infectious diseases and antibiotic treatment. He is Editor-in-Chief of The Journal of Hospital Infection and an Assistant Editor of International Journal of Antimicrobial Agents and the Journal of Pediatric Infectious Diseases.
Dr Shelley Rahman Haley
Consultant Cardiologist, Royal Brompton and Harefield NHS Foundation Trust
Biography to follow.
Professor Steve Halligan
Professor of Radiology, University College London
Biography to follow.
Professor Neil Hawkins
Professor of Health Technology Assessment, University of Glasgow
Neil Hawkins is a Professor of Health Technology Assessment (HTA) at the University of Glasgow, Scotland. He is deputy director of the National Institute of Health Research (NIHR) funded Complex Reviews Support Unit (CRSU). His research interests include methods development for evidence synthesis and decision-analytic modelling and the use of “development focussed” HTA to support decision-making regarding the development of, and investment in, nascent healthcare technologies.
He holds post-graduate degrees in Pharmacology, Health Economics and Applied Statistics and an MBA. He has worked in the pharma, academic, and consultancy sectors in roles spanning basic pharmacological research, clinical development, epidemiology, and health technology assessment.
Mr John Hitchman
John Hitchman is a retired Chartered Architect who was Principal of a private practice in Co. Durham. He has served on standard committees for a number of statutory and voluntary organisations and currently sits on the Lord Chancellor's Advisory Committee for the Selection of Magistrates. John is a member of the Lay Group of the Royal College of Anaesthetists where he serves on a range of the College's committees. He is also the lay representative on Peer Review Panels for the Association of Paediatric Anaesthetists of Great Britain and Ireland. John's particular interest in the NHS is the improvement of the patient experience especially for the young and the vulnerable.
Professor Chris Hyde
Professor of Public Health & Clinical Epidemiology, Exeter Test Group, University of Exeter Medical School
Chris Hyde trained in medicine and public health in London and East Anglia respectively. His expertise is in systematic reviews and health technology assessments, particularly in the context of providing support to policy-makers. In this respect he has undertaken many reports for NICE, particularly its Technology Appraisal Programme.
During his career he has set up and directed the Aggressive Research Intelligence Facility (ARIF), an effectiveness information support service for commissioners in the West Midlands. Chris has also directed the West Midlands Health Technology Assessment Collaboration and been closely involved with the Systematic Reviews Initiative of the National Blood Service. He has long-standing connections with the Cochrane Collaboration and is an editor of the NHS HTA Monograph series. He is currently based at the Peninsula College of Medicine and Dentistry where he leads the Technology Appraisal Group in PenTAG.
He has a long-standing interest in the evaluation of tests and has done health technology assessments on many topics including automated cervical screening, hysteroscopy, prediction of pre-eclampsia and pre-term birth, PET/CT, orthopantomography and identifying genetic sub-types in diabetes. He is currently part of the UK Support Unit for Cochrane Diagnostic Test Accuracy Reviews based at the University of Birmingham; and a member of the Cochrane Diagnostics Test Accuracy Editorial Board.
Dr Sandeep Kapur BSc(Hons) MBBS MRCGP(Dist)
GP, south east London
Dr Sandeep Kapur is a GP in south east London. He undertook medical training at Guys & St Thomas’ Hospitals following which he completed an Internal Medicine training program from Case Western Reserve University, Cleveland, USA. He is a GMC PLAB examiner, CQC GP specialist advisor and is a member of the BNF Joint Formulary committee.
Mr Patrick McGinley ICMA, CGMA
Head of Costing and Service Line Reporting, Maidstone and Tunbridge Wells NHS Trust
Patrick started as a Trainee Accountant at St Bartholomew’s Hospital in 1983, and apart from a brief sojourn to the far NW of Scotland as a postmaster, has worked in the NHS ever since in a variety of roles and institutions including at the Royal London, Homerton, Whipps Cross and Great Ormond Street before moving to Maidstone & Tunbridge Wells
He is currently Head of Costing and SLR, and has implemented an automated system of calculating costs at a patient level, and firmly believes that improved costing can help the NHS to understand its business, and maximise the value of healthcare.
He has direct operational experience as a Programme Manager of an NHS Breast Screening Unit, to go with experience as a Management and Costing Accountant, and he has successfully completed two PFI projects (BLT and TWH) as financial lead to offset the significant number of hospitals that he has helped to shut over his career.
He is an active member of the HFMA Costing Special Interest Group, and is also a member of NHSI’s Costing Advisory Group and technical review group, is a reviewer for both NICE and NIHR, and has presented regularly at National events on Acute Costing Standards.
He was a member of tariff calculation groups for NCAT for Chemotherapy and Radiotherapy, is a Fellow of Royal Statistical Society and a member of HSUG. He lectures on statistics for journalists for RSS. He benchmarks costing approaches with international colleagues, and is a training mentor for the Chartered Institute of Management Accountants; understandably, he is therefore rarely allowed out on his own.
Dr Michael Messenger
Deputy Director and Scientific Manager - NIHR Diagnostic Evidence Co-operative Leeds
Dr Michael Messenger is the Deputy Director and Scientific Manager for the NIHR Diagnostic Evidence Co-Operative Leeds and is responsible for overseeing the delivery of high-quality scientific evidence on in-vitro diagnostics (IVD) for the NHS.
As the Principal Healthcare Scientist on a NIHR Applied Programme Grant for Research “Evaluating the benefits for patients and the NHS of new and existing biological fluid biomarkers in liver and renal disease” he has experience across many phases of the “diagnostic pipeline” including the development, validation and clinical evaluation of new diagnostic assays.
Mrs Alexandria Moseley
Alexandria holds a degree in International Finance from the Wharton School as well as a degree in product design from FIT in New York City. She has been a Wall Street trader, serial entrepreneur, business owner, industry consultant, lifestyle blogger, and health advocate.
Served for many years as an international lay reviewer for Juvenile Diabetes Research Foundation and as a member of the Diabetes Research Network, plus one year on the Lay Committee for Diabetes UK. Invited as a patient expert for two previous NICE committees formulating guidance on insulin pumps. She has a special interest in autoimmune diseases.
Dr Dermot Neely BSc, MD, FRCP, FRCPath
Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Victoria Infirmary, Newcastle Upon Tyne
Dermot Neely is a Consultant in Clinical Biochemistry and Metabolic Medicine in Newcastle Upon Tyne Hospitals NHS Trust and Associate Clinical Lecturer at the University of Newcastle. He trained in Belfast and has specialist interests in lipidology and cardiovascular research. He is Director of the Newcastle Supra-Regional Assay Service (SAS) Cardiovascular Biomarkers and Endocrine Laboratories and is Lead for Evaluation for the Newcastle NIHR Diagnostic Evidence Co-operative.
He has previously served as a member of the Guideline Development Group for the NICE Lipid Modification Guideline (CG67) Review and as a reviewer for the HTA Diagnostics Programme.
Dr Simon Richards PhD
VP, Regulatory Affairs, EME, Alere
Simon Richards is VP, regulatory Affairs EME for Alere. Originally a PhD Biochemist working on chemiluminescent assay techniques, he has worked in the Vaccines and Diagnostics industry for over 20 years. He began his career at Amersham/Johnson+Johnson as a scientist before transitioning into Quality and Regulatory roles of increasing seniority in DPC (now part of Siemens), Novartis, Axis-Shield and now Alere.
He is also the chair of the Regulatory Affairs Working party for the UK IVD Industry body, BIVDA.
Professor Mark Sculpher BA (Hons), MSc, PhD
Professor of Health Economics, Centre for Health Economics, University of York
Mark Sculpher has worked in the field of economic evaluation and health technology assessment for over 25 years. He has researched in a range of clinical areas including heart disease and cancer, and evaluated therapeutic and diagnostic technologies He has also contributed to methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty. He has over 200 peer-reviewed publications and is a co-author of two major textbooks in the area.
Mark is a member of the UK National Institute of Health Research (NIHR) College of Senior Investigators. He has also been a member of the NICE Technology Appraisal and Public Health Interventions Advisory Committees. He chaired NICE's 2004 Task Group on methods guidance for economic evaluation; and has also advised health systems internationally on HTA methods including those in Ireland, Portugal, France and New Zealand. He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme and currently sits on the UK Medical Research Council's Methodology Research Panel.
Professor Matt Stevenson BSc, PhD
Director of the School of Health and Related Research Technology Assessment Group
Matt studied Operational Research at Lancaster University where he received his doctorate. He worked for the University of Sheffield for over 20 years, during which time he conducted cost-effectiveness analyses primarily for the National Institute for Health Research.
Matt is Director of the School of Health and Related Research Technology Assessment Group, an academic group undertaking modelling work to provide data for NICE technology and diagnostic appraisals. He is also a member of our technology appraisal committee, as well as our decision support unit.
Dr Nick Summerton
GP, East Yorkshire
Nick Summerton is a general practitioner and public health physician with specific interests in diagnostics and screening. He is also a member of the Royal College of General Practitioners, a fellow of the Faculty of Public Health and has been awarded a doctorate from the University of Oxford.
In addition to working as a general practitioner since 1988, he has occupied a variety of parallel positions as a Medical Director, Clinical Lead (BUPA & BMI), and Senior Lecturer/Reader. He has also written books on cancer diagnosis, primary care diagnostics, health checks and Roman medicine.
Professor Anthony Wierzbicki BA, MA, BM, BCh, DPhil, DM
Consultant in Metabolic/Chemical Pathology, St Thomas Hospital
Professor Anthony Wierzbicki is a consultant in metabolic medicine & chemical pathology and has been director of the lipid unit at St. Thomas and Guy’s Hospitals in 1994. His work in the field of atherosclerosis has led to appointments as a Fellow of the National Association of Clinical Biochemistry (USA) and the American Heart Association (arteriosclerosis and blood pressure sections). He has been a trustee of HEART-UK (the UK cholesterol charity) and chairman of this charity’s medical and scientific committee.
His clinical interests are in diagnostics, cardiovascular risk quantification systems and the molecular genetics of hyperlipidaemia. He is a member of the SE London cardiac network treatment and vascular risk guideline groups.
He was a member of the writing group of the International Familial Hypercholesterolaemia guidelines. He has served at NICE on Technology Appraisal panels, the familial hypercholesterolaemia guideline group (CG71) and chaired the Lipids and Cardiovascular risk assessment guideline (CG181).